GRFS - Grifols SA

8.59
0   0%

Share volume: 404,947
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$8.59
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
56%
Profitability 43%
Dept financing 43%
Liquidity 71%
Performance 69%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.58%
1 Month
-10.33%
3 Months
-4.34%
6 Months
-15.03%
1 Year
10.13%
2 Year
22.71%
Key data
Stock price
$8.59
P/E Ratio 
23.79
DAY RANGE
$8.44 - $8.64
EPS 
$1.21
52 WEEK RANGE
$6.19 - $11.14
52 WEEK CHANGE
$10.13
MARKET CAP 
7.948 B
YIELD 
N/A
SHARES OUTSTANDING 
261.425 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,042,155
AVERAGE 30 VOLUME 
$688,890
Company detail
CEO: Raimon G. Roura
Region: US
Website: grifols.com
Employees: 26,300
IPO year: 2011
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Company offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.

Recent news